Press release
Angioedema Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceut
The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Angioedema Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Angioedema Market.
Some of the key takeaways from the Angioedema Pipeline Report: https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Angioedema treatment therapies with a considerable amount of success over the years.
• Angioedema companies working in the treatment market are ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, and others, are developing therapies for the Angioedema treatment
• Emerging Angioedema therapies in the different phases of clinical trials are- ADX-324, BMN 331, NTLA-2002, STAR-0215, Donidalorsen, Sebetralstat, CSL312, and others are expected to have a significant impact on the Angioedema market in the coming years.
• In January 2025, Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on advancing medicine with CRISPR-based therapies, has announced that the first patient has been dosed in the global Phase 3 study of NTLA-2002 for treating hereditary angioedema (HAE). NTLA-2002 is a proprietary investigational in vivo CRISPR-based therapy being developed as a single-dose treatment for this potentially life-threatening condition. Intellia plans to complete enrollment by the second half of 2025 and intends to submit a biologics license application (BLA) in 2026, with the goal of launching the therapy in the U.S. by 2027.
• In January 2025, KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The company has also submitted a New Drug Application (NDA) for sebetralstat to the Agency. If approved, sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older, will become the first oral on-demand treatment for HAE in Japan.
• In October 2024, Intellia Therapeutics, a US-based biotechnology company, launched the Phase III HAELO clinical trial for NTLA-2002, an investigational in-vivo gene editing therapy aimed at treating hereditary angioedema (HAE). This multinational, placebo-controlled study will evaluate the therapy's efficacy and safety in 60 adult participants diagnosed with Type I or Type II HAE.
Angioedema Overview
Angioedema is a condition characterized by the swelling of the deeper layers of the skin, often occurring in areas such as the eyes, lips, tongue, throat, hands, feet, or genitals. This swelling is caused by the accumulation of fluid in the tissues beneath the skin.
Get a Free Sample PDF Report to know more about Angioedema Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Angioedema Drugs Under Different Phases of Clinical Development Include:
• ADX-324: ADARx Pharmaceuticals
• BMN 331: BioMarin Pharmaceutical
• NTLA-2002: Intellia Therapeutics
• STAR-0215: Astria Therapeutics
• Donidalorsen: Ionis Pharmaceuticals
• Sebetralstat: KalVista Pharmaceuticals
• CSL312: CSL Behring
Angioedema Route of Administration
Angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Angioedema Molecule Type
Angioedema Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Angioedema Pipeline Therapeutics Assessment
• Angioedema Assessment by Product Type
• Angioedema By Stage and Product Type
• Angioedema Assessment by Route of Administration
• Angioedema By Stage and Route of Administration
• Angioedema Assessment by Molecule Type
• Angioedema by Stage and Molecule Type
DelveInsight's Angioedema Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Angioedema product details are provided in the report. Download the Angioedema pipeline report to learn more about the emerging Angioedema therapies
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Angioedema Therapeutics Market include:
Key companies developing therapies for Angioedema are - BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals Inc., Intellia Therapeutics, and others.
Angioedema Pipeline Analysis:
The Angioedema pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Angioedema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angioedema Treatment.
• Angioedema key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Angioedema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Angioedema market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Angioedema drugs and therapies
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Angioedema Pipeline Market Drivers
• Increasing Prevalence of Angioedema, increase in research and developmental activities are some of the important factors that are fueling the Angioedema Market.
Angioedema Pipeline Market Barriers
• However, high-cost associated with the treatment, misdiagnosis of the disease and other factors are creating obstacles in the Angioedema Market growth.
Scope of Angioedema Pipeline Drug Insight
• Coverage: Global
• Key Angioedema Companies: ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, and others
• Key Angioedema Therapies: ADX-324, BMN 331, NTLA-2002, STAR-0215, Donidalorsen, Sebetralstat, CSL312, and others
• Angioedema Therapeutic Assessment: Angioedema current marketed and Angioedema emerging therapies
• Angioedema Market Dynamics: Angioedema market drivers and Angioedema market barriers
Request for Sample PDF Report for Angioedema Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/angioedema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Angioedema Report Introduction
2. Angioedema Executive Summary
3. Angioedema Overview
4. Angioedema- Analytical Perspective In-depth Commercial Assessment
5. Angioedema Pipeline Therapeutics
6. Angioedema Late Stage Products (Phase II/III)
7. Angioedema Mid Stage Products (Phase II)
8. Angioedema Early Stage Products (Phase I)
9. Angioedema Preclinical Stage Products
10. Angioedema Therapeutics Assessment
11. Angioedema Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Angioedema Key Companies
14. Angioedema Key Products
15. Angioedema Unmet Needs
16 . Angioedema Market Drivers and Barriers
17. Angioedema Future Perspectives and Conclusion
18. Angioedema Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Angioedema Market https://www.delveinsight.com/report-store/angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Angioedema Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Angioedema Epidemiology https://www.delveinsight.com/report-store/angioedema-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Angioedema Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Angioedema Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ADARx Pharmaceuticals, BioMarin Pharmaceutical, Intellia Therapeutics, Astria Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceut here
News-ID: 3849770 • Views: …
More Releases from DelveInsight Business Research
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
Global Medical Device Contract Manufacturing Market to Witness ~12% CAGR by 2032 …
DelveInsight's Medical Device Contract Manufacturing Market Insights report delivers a detailed evaluation of the current and projected global market for medical device contract manufacturing. The report examines the market shares of leading companies, growth drivers, barriers, market trends, and emerging opportunities, providing a holistic understanding of the competitive landscape.
The market is currently witnessing robust growth due to rising demand for sophisticated yet cost-effective medical devices. Contributing factors include the increasing…
KRAS Inhibitors Market Analysis 2034: Competitive Landscape, Approvals, Clinical …
DelveInsight's latest report, "KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies", provides an extensive analysis of the global KRAS inhibitors landscape, offering insights into emerging therapies, current treatment practices, market size, and future growth projections. The report evaluates the market across seven major markets (7MM), including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and…
Biktarvy Market Outlook 2034: Driving Global HIV Treatment Leadership and Expand …
The Biktarvy market continues to dominate the global HIV treatment landscape, driven by strong prescription growth, expanding indications, and robust commercial strategies by Gilead Sciences. As a single-tablet, once-daily antiretroviral therapy, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) has cemented its position as a preferred regimen for people living with HIV (PLWH) across multiple patient populations, including treatment-naïve, treatment-experienced, and pediatric populations.
According to the latest analysis, Biktarvy maintains market leadership in both first-line…
More Releases for Angioedema
Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033.
Hereditary Angioedema Market Overview
The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
Angioedema Treatment Market 2022 | Detailed Report
This report provides an informative view about the competitive aspect of the global market. It includes detailed picture of the exhibition of a portion of the essential global players working in the Angioedema Treatment market. The research study also provides historical record with profits predictions and forecasts from 2022 to 2028. Also, the business manufacturing of the notable manufacturers is also emphasized with technical data in the report.
This report is…
Hereditary Angioedema Therapeutics Market - Forecast to 2026
As per the research conducted by GME, the Global Hereditary Angioedema Therapeutics Market will grow with a CAGR value of 8.2%. Population growth, as well as lifestyle changes, improved insurance programs, and increased efforts by pharmaceutical and biotechnology companies to develop new products and solutions for the industry, are expected to fuel market revenue for Hereditary Angioedema in the years ahead.
Browse 153 Market Data Tables and 113 Figures spread through…
